Efficacy of a seal-wing paclitaxel-eluting balloon catheters in
the treatment of bare metal stent restenosis

J 2017

Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis

PLEVA, L., P. KUKLA, J. ZAPLETALOVA a Ota HLINOMAZ

Základní údaje

Originální název

Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis

Autoři

PLEVA, L. (203 Česká republika), P. KUKLA (203 Česká republika), J. ZAPLETALOVA (203 Česká republika) a Ota HLINOMAZ (203 Česká republika, garant, domácí)

Vydání

BMC Cardiovascular Disorders, London, Biomed Central Ltd, 2017, 1471-2261

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.812

Kód RIV

RIV/00216224:14110/17:00099995

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s12872-017-0602-6

UT WoS

000404166900001

Klíčová slova anglicky

In-stent restenosis; Paclitaxel-elution balloon; Drug-eluting stent

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 3. 2018 17:07, Soňa Böhmová

Anotace

V originále

Background: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) with iopromide-coated PEB and everolimus-eluting stents (EES) for treating bare metal stent restenosis (BMS-ISR). Methods: We enrolled 64 patients with 69 BMS-ISR. The control group comprised patients from the iopromide-PEB and EES arms of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis and 12-month major adverse cardiac events (MACE). Results: Compared to iopromide-coated PEB, seal-wing PEB was associated with significantly higher 12-month LLL (0.30 vs. 0.02 mm; p < 0.0001), repeated binary restenosis (28.12% vs. 8.7%; p = 0.012), 12-month MACE (26.98% vs. 10.29%; p = 0.003), and target vessel revascularization (TVR; 20.63% vs. 7.35%; p = 0.009). Compared to EES, no significant differences were found in the 12-month LLL (0.30 vs. 0.19 mm; p = 1.000), repeated binary restenosis (28.12% vs. 19.12%; p = 0.666), 12-month MACE (26.98% vs. 19.12%; p = 0.102) or TVR (20.63% vs. 16.18%; p = 0.360). Conclusion: BMS-ISR treatment using seal-wing PEB led to significantly higher 12-month LLL, repeated binary restenosis, MACE, and TVR compared to iopromide-coated PEB. However, no significant differences were found in comparison with EES.

Citovat

PLEVA, L., P. KUKLA, J. ZAPLETALOVA a Ota HLINOMAZ. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. BMC Cardiovascular Disorders. London: Biomed Central Ltd, 2017, roč. 17, č. 6, s. 1-9. ISSN 1471-2261. Dostupné z: https://dx.doi.org/10.1186/s12872-017-0602-6.

@article{1408003,
   author = {Pleva, L. and Kukla, P. and Zapletalova, J. and Hlinomaz, Ota},
   article_location = {London},
   article_number = {6},
   doi = {http://dx.doi.org/10.1186/s12872-017-0602-6},
   keywords = {In-stent restenosis; Paclitaxel-elution balloon; Drug-eluting stent},
   language = {eng},
   issn = {1471-2261},
   journal = {BMC Cardiovascular Disorders},
   title = {Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis},
   volume = {17},
   year = {2017}
}

TY  - JOUR
ID  - 1408003
AU  - Pleva, L. - Kukla, P. - Zapletalova, J. - Hlinomaz, Ota
PY  - 2017
TI  - Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis
JF  - BMC Cardiovascular Disorders
VL  - 17
IS  - 6
SP  - 1-9
EP  - 1-9
PB  - Biomed Central Ltd
SN  - 14712261
KW  - In-stent restenosis
KW  - Paclitaxel-elution balloon
KW  - Drug-eluting stent
N2  - Background: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) with iopromide-coated PEB and everolimus-eluting stents (EES) for treating bare metal stent restenosis (BMS-ISR). Methods: We enrolled 64 patients with 69 BMS-ISR. The control group comprised patients from the iopromide-PEB and EES arms of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis and 12-month major adverse cardiac events (MACE). Results: Compared to iopromide-coated PEB, seal-wing PEB was associated with significantly higher 12-month LLL (0.30 vs. 0.02 mm; p < 0.0001), repeated binary restenosis (28.12% vs. 8.7%; p = 0.012), 12-month MACE (26.98% vs. 10.29%; p = 0.003), and target vessel revascularization (TVR; 20.63% vs. 7.35%; p = 0.009). Compared to EES, no significant differences were found in the 12-month LLL (0.30 vs. 0.19 mm; p = 1.000), repeated binary restenosis (28.12% vs. 19.12%; p = 0.666), 12-month MACE (26.98% vs. 19.12%; p = 0.102) or TVR (20.63% vs. 16.18%; p = 0.360). Conclusion: BMS-ISR treatment using seal-wing PEB led to significantly higher 12-month LLL, repeated binary restenosis, MACE, and TVR compared to iopromide-coated PEB. However, no significant differences were found in comparison with EES.
ER  -

PLEVA, L., P. KUKLA, J. ZAPLETALOVA a Ota HLINOMAZ. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. \textit{BMC Cardiovascular Disorders}. London: Biomed Central Ltd, 2017, roč.~17, č.~6, s.~1-9. ISSN~1471-2261. Dostupné z: https://dx.doi.org/10.1186/s12872-017-0602-6.

Podrobný výpis o publikaci